Skip to Content

Efficacy of 1L Treatment Does Not Predict Efficacy of 2L Cabozantinib for Patients with mRCC

Interview: Real-world study underscores cabozantinib’s effectiveness as a second-line therapy for mRCC, regardless of prior first-line treatment outcomes.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top